No Data
Shandong Jincheng Pharmaceutical Group (300233.SZ): Currently, the company's astaxanthin products are mainly applied in fields such as aquaculture and agricultural fertilizers.
On December 23, Glonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) stated on the investor interaction platform that its astaxanthin products are currently mainly applied in fields such as aquaculture and fertilizers.
Shandong Jincheng Pharmaceutical Group (300233.SZ): Jincheng Jinsuo injectable Cefoperazone Sodium and Sulbactam Sodium has obtained the approval notification for the Pharmaceutical supplementary application.
On December 20, Glonghui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its holding subsidiary Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd. (hereinafter referred to as "Jincheng Jinsuo") has recently received the approval notice for the supplementary application of injectable cefoperazone sodium and sulbactam sodium from the National Medical Products Administration (Certificate No.: 2024B05973, 2024B05974). Upon review, this product has passed the consistency evaluation for the quality and efficacy of generic drugs. This product is suitable for treating infections of the upper and lower respiratory tract caused by sensitive bacteria; upper and lower urinary tract infections; peritonitis, cholecystitis, cholangitis and Other abdominal infections.
Further Weakness as Shandong Jincheng Pharmaceutical Group (SZSE:300233) Drops 8.2% This Week, Taking Three-year Losses to 50%
Shandong Jincheng Pharmaceutical Group (300233.SZ): Jincheng Tailruibapate tablets have obtained the pharmaceutical registration certificate.
Gelonghui, December 3rd | shandong jincheng pharmaceutical group (300233.SZ) announced that its wholly-owned subsidiary, Peking Jincheng Tail Pharmaceutical Co., Ltd. (referred to as "Jincheng Tail" or "subsidiary" below), has received the registration certificate for the Rupatadine tablets issued by the National Medical Products Administration (Certificate No.: 2024S02910). Rupatadine tablets were registered for Class 4 chemical drugs application, and after approval, they are considered to have passed the consistency evaluation of generic drug quality and efficacy. Rupatadine tablets are mainly used to improve gastric ulcers, acute gastritis, and acute exacerbation of chronic gastritis with gastric mucosal lesions, including erosion, bleeding, congestion, and edema.
shandong jincheng pharmaceutical group (300233.SZ): jincheng tai er chlorhexidine production line successfully passed pharmaceutical GMP compliance inspection
Gelonghui November 25th, shandong jincheng pharmaceutical group (300233.SZ) announced that its wholly-owned subsidiary, Peking Jincheng Tail Pharmaceutical Co., Ltd. (hereinafter referred to as "Jincheng Tail"), has received the "Drug GMP Compliance Inspection Inform Letter" (Number: Jingya Jin GMP [2024] 020072) approved and issued by the Beijing Drug Administration. Inspection scope and related production workshops, production lines: Chloroquine Phosphate (Registration No: Y20220000707) (In the western area of Langang Economic and Technological Development Zone, Cangzhou City, Hebei Province, north of Erliu Road and east of Weli Road, Workshop 1: Chloroquine Phosphate production.
Shandong Jincheng Pharmaceutical Group (300233.SZ): Equipped with a composite, multi-technology biosynthesis and chemical synthesis dual platform.
Gelonghui, November 21st | Shandong Jincheng Pharmaceutical Group (300233.SZ) stated in recent investor relations activities that the company has a composite, multi-technical dual platform for biological synthesis and chemical synthesis, with about 2,000 chemical synthesis team members and 400 synthetic biologists. The dual-platform advantage solves the problems of low efficiency and high cost in traditional products and traditional industries. The company's product selection is focused on the pharmaceutical + health industry, with certain technological barriers.
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
No Data
